A Pediatric Case of Short Bowel Syndrome Treated With Teduglutide (Revestive^®)

Abstract

We report the case of a patient presenting with short bowel syndrome treated with teduglutide. A 10-year-old boy was born with a short bowel lacking the ileum and colon. For nutritional management, a central venous catheter (CVC) was indwelled from the age of two years, and in addition to oral intake, total parenteral nutrition was started. He had several catheter-related bloodstream infections (CRBSIs) and the CVC had to be replaced. In 2021, the use of teduglutide, a glucagon-like peptide-2 analog preparation for the treatment of short bowel syndrome, was covered by National Health Insurance in Japan. One year has passed since he started using teduglutide at our hospital. Endoscopic examination revealed villus elongation and improvement in stool quality. His height and weight were normal for his age, and he was less dependent on parenteral nutrition and showed increased resistance to CRBSIs. As adverse events, he felt abdominal pain and had excess gas, which improved over time. We have shown the effects of teduglutide on a patient with short bowel syndrome who had a colostomy.